Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Schedule of Segment Information

The tables below present segment information reconciled to total Company loss from operations, with segment operating loss including gross profit less direct research and development expenses and direct selling, general and administrative expenses to the extent specifically identified by segment:

	Three Months Ended June 30, 2020
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	1,567		$	10		$	-		$	1,577
Gross margin		889			6			-			895
Research and development expenses		346			105			385			836
Depreciation and amortization expense		47			-			-			47
Selling, general and administrative expenses		1,348			137			125			1,610
Change in fair value of contingent consideration		-			-			-			-
Total operating expenses		1,741			242			510			2,493
Loss from operations	$	(852	)	$	(236	)	$	(510	)	$	(1,598	)

	Six Months Ended June 30, 2020
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	4,078		$	28		$	-		$	4,106
Gross margin		2,369			17			-			2,386
Research and development expenses		656			157			586			1,399
Depreciation and amortization expense		93			-			-			93
Selling, general and administrative expenses		3,063			262			235			3,560
Change in fair value of contingent consideration		(42	)		-			-			(42	)
Total operating expenses		3,770			419			821			5,010
Loss from operations	$	(1,401	)	$	(402	)	$	(821	)	$	(2,624	)

	Three Months Ended June 30, 2019
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	2,309		$	-		$	-		$	2,309
Gross margin		1,367			-			-			1,367
Research and development expenses		247			186			360			793
Depreciation and amortization expense		48			-			-			48
Selling, general and administrative expenses		1,352			-			51			1,403
Change in fair value of contingent consideration		(9	)		-			-			(9	)
Total operating expenses		1,638			186			411			2,235
Loss from operations	$	(271	)	$	(186	)	$	(411	)	$	(868	)

	Six Months Ended June 30, 2019
	(in thousands)
	Water Filtration			Pathogen Detection			Renal Products			Nephros, Inc. Consolidated
Total net revenues	$	4,078		$	-		$	-		$	4,078
Gross margin		2,365			-			-			2,365
Research and development expenses		467			312			770			1,549
Depreciation and amortization expense		98			-			-			98
Selling, general and administrative expenses		2,821			-			85			2,906
Change in fair value of contingent consideration		(19	)		-			-			(19	)
Total operating expenses		3,367			312			855			4,534
Loss from operations	$	(1,002	)	$	(312	)	$	(855	)	$	(2,169	)